RDRavi Dhawan

Ravi Dhawan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ravi Dhawan has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Financial Toxicity in Craniofacial Surgery: A Scoping Review of Patient-Level Direct and Indirect Costs

    by Ravi Dhawan, Gabriella Glassman, Alexandra Boric, Amelia Fogle, Renée Roberts, Ambika Menon, Orr Shauly, Kendall Brooks, Albert Losken, Colin Brady, et al.

    Background: Financial toxicity (FT), the harmful effects of treatment-related financial burden on patients and families, is increasingly recognized in surgical care. Patients with craniofacial conditions may be uniquely vulnerable given the prolonged, iterative and multidisciplinary nature of treatment. However, FT in craniofacial surgery remains inadequately characterized. We conducted the first scoping review to map the scope, measurement, and drivers of FT in craniofacial care. Methods: Five electronic databases (PubMed, Embase, Scopus, Web of Science, and Global Health) were searched from inception through December 1, 2025, following PRISMA guidelines. English-language original research reporting patient-level financial outcomes in craniofacial populations was included. Two authors independently screened records and extracted data. Risk of bias was assessed using validated tools for observational designs. Results: Of 2847 citations identified, 18 studies met inclusion criteria, with a total of 18 224 participants. Most studies (83.3%) were published after 2020, and 72.2% originated from high-income countries. The predominant diagnosis was cleft lip and/or palate (15 studies), and 88.9% enrolled pediatric populations. No study employed a validated FT-specific instrument, and only 2 provided an explicit FT definition. Risk of bias was moderate in 10 (55.6%) and high in 8 studies (44.4%). Cumulative OOPcosts reached $45 140, and lifetime care costs reached $73 398 Canadian Dollars across a median of 148.5 healthcare interactions. Travel and indirect costs were the most frequently measured domain (55.6% of studies). Conclusions: Financial toxicity in craniofacial surgery is substantial but inconsistently measured. Development and validation of specialty-specific FT instruments should be prioritized to enable standardized measurement.

  • Plastic surgery workforce distribution: A national analysis

    by Ravi Dhawan, Julianna Zeepvat, Amelia Fogle, Alexandra Boric, Orr Shauly, Troy Marxen, Gabriela Garcia Nores, Paul A. Ghareeb, Albert Losken


  • Open Access

    Risk of Recall Among Plastic Surgery Devices Cleared Through the FDA 510(k) Pathway

    by Ravi Dhawan, Alexandra Boric, Orr Shauly, Troy Marxen, Anjali Om, Kendall Brooks, Gabriela García Nores, Albert Losken

    Background: The FDA 510(k) pathway is the predominant route by which medical devices reach the US market. Previous studies have examined recall risk across broad FDA panels, but none have characterized plastic surgery devices or compared recall patterns across subcategories within the field. Objectives: The aim of this study was to determine the rate and severity of FDA recalls among 510(k)-cleared plastic surgery devices, compare recall risk across subcategories, and benchmark against all other 510(k) devices. Methods: All 510(k)-cleared devices (2008-2023) were obtained from the FDA premarket notification database. Two reviewers classified 234 surgery panel product codes, identifying 103 plastic surgery codes (3194 devices) in 8 subcategories. Each device was matched to the FDA recall database by its 510(k) number. All remaining 510(k) devices (n = 45,182) served as comparator. Recall rates were compared using χ2 tests and risk ratios (RR); time to first recall was modeled with Cox proportional hazards regression with Bonferroni correction. Results: Of 3194 plastic surgery devices, 197 (6.2%) were recalled, including 11 Class I recalls (0.3%). The recall rate for all other 510(k) devices was 11.4% (RR, 0.54; 95% CI, 0.47-0.62; P < .001). After Bonferroni correction, 4 subcategories had elevated recall hazard vs lasers and energy: implants and fixation (hazard ratio [HR], 3.64), negative pressure wound therapy (HR, 2.53), surgical mesh and acellular dermal matrices (HR, 2.46), and wound closure (HR, 2.01). Conclusions: Plastic surgery 510(k) devices had a lower recall rate than nonplastic surgery devices, although risk varied substantially across subcategories. These data provide a specialty-specific baseline for postmarket device surveillance. Level of Evidence: 5 (Therapeutic): For image description, please refer to the figure legend and surrounding text.

  • Submandibular Gland Reduction in the Modern Necklift Surgery: A Systematic Literature Review

    by Orr Shauly, Ravi Dhawan, Daniel J Gould

    Submandibular gland prominence can undermine aesthetic outcomes in neck and lower face rejuvenation, even after deep-plane facelifts and platysmaplasty. In selected patients, gland reduction has emerged as an effective adjunct to improve cervicomental contour. In this systematic review, the authors analyze 51 studies involving 2971 patients undergoing submandibular gland reduction across 6 surgical approaches, including transcervical, necklift-integrated, intraoral, retroauricular, endoscopic, and robotic-assisted techniques. The overall complication rate was 15.1%, with marginal mandibular nerve injury being most common (9.8%). Minimally invasive methods, particularly endoscopic and intraoral, showed lower hematoma rates and faster recovery with high patient satisfaction. Retroauricular approaches yielded excellent aesthetic outcomes but had the highest nerve injury rates. LigaSure-assisted and partial reductions reduced bleeding and preserved function. Despite generally favorable results, variation in technique, outcome reporting, and patient selection limits broader adoption. Standardized protocols and prospective studies are needed to optimize safety, aesthetic benefit, and long-term results in submandibular gland contouring for facial rejuvenation. Level of Evidence: 3 (Therapeutic)


  • Private equity consolidation in anaesthesiology: trends and sector‐specific investment patterns from 2006 to 2024

    by Ravi Dhawan, Johnathan J. Choi, Dario von Wedel, Maximilian S. Schaefer, Denys Shay


  • Increasing Private Equity Investments in Plastic Surgery Practices in the United States: Analysis of Trends and Consolidation

    by Ravi Dhawan, Kendall Brooks, Orr Shauly, Denys Shay, Anjali Om, Albert Losken, Paul A Ghareeb

    Background: Private equity (PE) investment in healthcare has expanded rapidly, particularly in plastic surgery, where rising demand for aesthetic procedures presents attractive financial opportunities. Although PE backing may enhance operational efficiencies, concerns exist regarding its potential impact on care quality, patient outcomes, and healthcare costs. Objectives: The authors of this study examine PE acquisitions of US plastic surgery practices, identifying trends in investment growth, geographic distribution, and the financial models adopted by PE-backed practices. Methods: In this cross-sectional study, the authors analyzed PE acquisitions of US plastic surgery practices from January 1, 2000 to July 1, 2024. Data were obtained from PitchBook, verified through practice websites and follow-up inquiries. The analysis focused on acquisition trends, insurance acceptance policies, and the geographic distribution of PE-backed practices. Results: Between 2000 and 2023, PE-backed acquisitions in plastic surgery grew by 4300% in practice volume and 7630% in capital investment. Acquisitions were concentrated in states, such as Texas, Florida, and New York. PE investment was prominent in general, facial, and oculoplastic surgery practices, with a preference for cash-only models, particularly in specialized fields. Many practices employed few plastic surgeons, relying instead on aesthetic clinicians. Conclusions: PE consolidation in plastic surgery is expanding rapidly, driven by demand for elective procedures. Although PE investment brings financial and operational advantages, it raises concerns about healthcare quality and equity. Further research comparing PE and non-PE-owned practices is necessary to guide policies ensuring patient care quality and access.


  • Analysis of venture capital investments in anaesthesiology companies from 2000 to 2024

    by Ravi Dhawan, Dario von Wedel, Simone Redaelli, Maximilian S. Schaefer, Denys Shay


  • Open Access

    Growth in FDA-Approved Artificial Intelligence Devices in Plastic Surgery: A Key Look Into the Future

    by Ravi Dhawan, Orr Shauly, Denys Shay, Kendall Brooks, Albert Losken

    Ravi Dhawan, MS, Orr Shauly, MD, Denys Shay, MD, Kendall Brooks, MD, MSCE, Albert Losken, MD, FACS; Growth In FDA-Approved AI Devices In Plastic Surgery: A